Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Clinical trial NCT07237100 · RECRUITING

Trial details

NCT number: NCT07237100
Sponsor: Kevin Kim, MD
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Unresectable Melanoma Metastatic Melanoma

Start date: 2025-10-13
Primary completion: 2027-10-13
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.